Drugs / 89Zr-DFO-MSTP2109A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01774071 | Jan 2013 → May 2023 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-DFO-MSTP2109A | “The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long...” NCT01774071 ↗ |
| Modality | Protein / enzyme biologic | “DFO-MSTP2109A is an antibody” NCT01774071 ↗ |
| Target | STEAP1 | “works against STEAP1 - found on the surface of prostate cancer cells” NCT01774071 ↗ |